Formulation and characterization of ascorbic acid-based zinc oxide nanoparticles for assessing antidiabetic and neuroprotective effects in STZ-induced diabetic rats
Source abstract
Abstract
Ascorbic acid (AA) has strong antioxidant and anti-diabetic activities; nevertheless, its therapeutic value is restricted due to rapid degradation, low-bioavailability and short systemic retention. To address these constraints, this study describes the development of a green-synthesized zinc oxide nanoparticle (ZnO NP)-based delivery system functionalized with AA (ZnO-AA NPs) and assesses its antidiabetic and neuroprotective effects. AA-assisted precipitation method was used to develop ZnO-AA NPs, which were then characterized by dynamic light scattering (DLS), zeta potential (ZP), scanning electron microscopy (SEM), FTIR spectroscopy and X-ray diffraction (XRD). The nanoparticles had a homogeneous size (∼38 nm), good colloidal stability and a crystalline wurtzite structure. In vitro, ZnO-AA NPs showed dose-dependent inhibition of α-amylase and α-glucosidase. In vivo, oral ZnO-AA NPs (25 and 50 mg/kg) significantly improved glycaemic control, lipid profile and antioxidant enzyme levels compared to free AA (*p* < 0.01, *p* < 0.001; one-way/two-way ANOVA). ZnO-AA NPs dramatically reduced diabetes-related cognitive impairment, resulting in improved performance in the Morris water maze (MWM) and open field tests (OFTs) (*p* < 0.001), decreased hippocampal acetylcholinesterase (AChE) activity and preserved neuronal architecture. Overall, the ZnO-AA nanoformulation represents a multifunctional nanomedicine technique that improves the therapeutic efficacy of AA and has considerable promise for the treatment of diabetes and its associated neurodegenerative consequences.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Natural Antidiabetic Agents Studies · Advanced Drug Delivery Systems · Biochemical effects in animals
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacology, Faculty of Pharmacy, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University
Department of Pharmaceutics, College of Pharmacy, King Khalid University
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdul Aziz University
Department of Pharmacology, Orotta College of Medicine and Health Science
Funding
Deanship of Scientific Research, King Khalid University
References (54)
Show source-provided references
1. 10.4239/wjd.v14.i2.9210.4239/wjd.v14.i2.92 ↗
2. 10.3390/ijms22221236610.3390/ijms222212366 ↗
3. Barbiellini AC, Fayosse A, Dumurgier J, et al. Association between age at diabetes onset and subsequent risk of dementia. JAMA. 2021;325(16):1640–1649.10.1001/jama.2021.4001 ↗
4. 10.3390/ijms2316926710.3390/ijms23169267 ↗
5. 10.1016/j.arr.2019.10094410.1016/j.arr.2019.100944 ↗
6. 10.1016/j.biopha.2018.10.07010.1016/j.biopha.2018.10.070 ↗
7. 10.18295/2075-0528.133410.18295/2075-0528.1334 ↗
8. 10.1007/s13346-025-01962-110.1007/s13346-025-01962-1 ↗
9. 10.1007/s13346-025-01906-910.1007/s13346-025-01906-9 ↗
10. 10.1080/21688370.2022.206996610.1080/21688370.2022.2069966 ↗
11. 10.1016/j.molstruc.2022.13242010.1016/j.molstruc.2022.132420 ↗
12. 10.1186/s40199-015-0127-410.1186/s40199-015-0127-4 ↗
13. Sahoo RK, Rani S, Kumar V, et al. Zinc oxide nanoparticles for bioimaging and drug delivery. Nanostructured zinc oxide. Amsterdam, Netherlands: Elsevier;.2021. p. 483–509.10.1016/B978-0-12-818900-9.00021-8 ↗
14. 10.1016/j.ijleo.2017.12.17410.1016/j.ijleo.2017.12.174 ↗
15. 10.1080/17518253.2025.245662410.1080/17518253.2025.2456624 ↗
16. 10.1002/nano.20240011010.1002/nano.202400110 ↗
17. 10.22270/jmpas.V10I6.256010.22270/jmpas.V10I6.2560 ↗
18. 10.3390/molecules2816612510.3390/molecules28166125 ↗
19. 10.3390/molecules2602029310.3390/molecules26020293 ↗
20. 10.1073/pnas.77.10.612910.1073/pnas.77.10.6129 ↗
21. 10.3390/ph1610136810.3390/ph16101368 ↗
22. 10.1016/j.jpi.2025.10042310.1016/j.jpi.2025.100423 ↗
23. 10.1002/jemt.2450910.1002/jemt.24509 ↗
24. 10.1007/s10735-024-10223-310.1007/s10735-024-10223-3 ↗
25. 10.1007/s11064-015-1780-110.1007/s11064-015-1780-1 ↗
26. 10.1016/0006-2952(61)90145-910.1016/0006-2952(61)90145-9 ↗
27. 10.1002/brb3.213910.1002/brb3.2139 ↗
28. 10.1016/j.saa.2013.04.07210.1016/j.saa.2013.04.072 ↗
29. 10.3762/bjnano.16.810.3762/bjnano.16.8 ↗
30. 10.3390/solids604005910.3390/solids6040059 ↗
31. 10.3390/biom1111169210.3390/biom11111692 ↗
32. 10.1155/2021/478622710.1155/2021/4786227 ↗
33. 10.1007/s00253-024-13355-410.1007/s00253-024-13355-4 ↗
34. 10.1038/s41598-024-67420-z10.1038/s41598-024-67420-z ↗
35. 10.1007/s13205-024-04125-010.1007/s13205-024-04125-0 ↗
36. 10.1007/s13346-025-01887-910.1007/s13346-025-01887-9 ↗
37. 10.1080/0886022X.2024.242969410.1080/0886022X.2024.2429694 ↗
38. Sujata VW, Mu M, et al. Green synthesis and bioactivity screening of zinc oxide nanoparticles: in vitro investigation of wound healing, antioxidant, and antibacterial properties. J Neonatal Surg. 2025;14(275):397–406.
39. 10.1007/s12011-023-04043-x10.1007/s12011-023-04043-x ↗
40. Hussein SA, El-Senosi YA, El-Dawy K, et al. Protective effect of zinc oxide nanoparticles on oxidative stress in experimentally induced diabetes in rats. Benha Vet Med J. 2023;27(2):405–414.
41. 10.1007/s13346-024-01721-810.1007/s13346-024-01721-8 ↗
42. 10.1208/s12249-015-0405-y10.1208/s12249-015-0405-y ↗
43. 10.3390/antiox1209167910.3390/antiox12091679 ↗
44. 10.3390/pr1007127310.3390/pr10071273 ↗
45. 10.3390/pharmaceutics1311193710.3390/pharmaceutics13111937 ↗
46. 10.1007/s13346-024-01710-x10.1007/s13346-024-01710-x ↗
47. 10.1002/jemt.2482610.1002/jemt.24826 ↗
48. 10.1002/slct.20250139510.1002/slct.202501395 ↗
49. 10.1016/j.micpath.2024.10713910.1016/j.micpath.2024.107139 ↗
50. 10.1515/gps-2024-022610.1515/gps-2024-0226 ↗
51. 10.1515/gps-2024-020310.1515/gps-2024-0203 ↗
52. 10.2147/IJN.S48718810.2147/IJN.S487188 ↗
53. 10.1080/02603594.2025.256160410.1080/02603594.2025.2561604 ↗
54. 10.1080/00387010.2025.249393210.1080/00387010.2025.2493932 ↗